The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Jim Cramer really, really wants to be negative about the market right now. But as hard as he tries, he just can't do it. There are too many good indicators swirling around to bring him down. The llamas can run around Sun City all they want—because Cramer sees plenty of stocks running wild along with them.
"I loved that Monster quarter. I told you I thought it was going to be a good one, but I didn't think it was going to be this good. MNST goes higher! "
Cramer's wild mood started first thing in the morning. As soon as he looked at the news on Thursday morning, he was greeted by fabulous bond rates in Europe. The Spanish 10-year bond rate was at 1.38 percent, and the Italian 10-year was at 1.42 percent—record lows for this region.
So what the heck do European bond rates have to do with the U.S. economy, and why is this important?
When Cramer saw these low interest rates, he was automatically taken back to just three years ago when these same bonds were yielding 7 percent. Both countries were in a liquidity crisis and were desperately trying to raise cash.
As a result, the U.S. markets were crushed, when the Dow dropped 900 points from 12,000, with a one-day decline of 400 points on the day that Italy's bonds hit 7 percent.
"So, we have a situation that's the polar opposite of something that caused our markets to get crushed. Isn't it a simple deduction to conclude that Europe should now be pushing our stocks higher?" the "Mad Money" host said.
One stock that is galloping higher, is Clean Harbors. Some may only think of hazardous waste when they think of this company, but in Cramer's mind, the stock is far from being disposable.
Clean Harbors is the largest hazardous waste disposal company in North America. Historically, the company played a large role in disaster relief, as well as helping dirty industries such as oil and gas maintain clean environments to meet regulatory requirements.
The stock took a hit in 2014 but has gotten its mojo back this year when management announced that it will spin off its oil and gas services business and its energy-focused lodging business into a separate, publicly traded company.
Clean Harbor also plans to increase focus on the recycled oil business that it acquired from Safety-Kleen a few years ago. And to boot, the company announced an awesome quarter when it reported earnings on Wednesday morning.
Could a struggling oil industry impact the stock this year? Cramer spoke with Clean Harbor CEO Alan McKim to gain further insight.
"Certainly, the country is doing better, but we have done a really good job of penetrating some of those oil and gas plays out there that have been pretty strong. Even with some of the recent laydowns of some of the drill rigs, we saw nice volume," McKim said.
Even with oil, Cramer sees good things in store so far. He keeps waiting for the greasy hammer to drop on oil, and has been nervously waiting for the oil renaissance to end and bring the economy to its knees.
"I figure it is only a matter of time before the over-levered, eyes-too-big-for-their-bank-account oil men go belly up, taking tens of thousands of jobs off the table with their recklessness and rendering boom cities into ghost towns," the "Mad Money" host said.
But it just hasn't happened. Texas hasn't fallen apart and taken down the banking system, and oil producers are still pumping. Cramer has a feeling that this oil crash is different from the others. Six months into the oil crash, and the economy hasn't crumpled.
Cramer suspects that the ripple effects just haven't been that visible in the U.S. economy. He outlined a few data points that clearly mark a difference in what was expected and what actually happened.
Considering that most thought an oil crash would cause the market to collapse, Cramer just hasn't seen the pain yet. There are just too many hedges, strong balance sheets and large loan capacities to allow for any real worry. Many companies seem to easily cut back, for now.
Maybe we won't endure the oil apocalypse?
"Maybe, just maybe, we won't, at least compared to the stunning positives that the price cut at the pump is giving individuals and businesses nationwide."
Cramer has found one speculative biopharmaceutical company that has already quadrupled and isn't done rewarding your portfolio, yet.
Receptos is a biopharmaceutical company that is focused on therapeutics for immune disorders. The stock took off in 2014, thanks to its clinical trial data for a drug called Ozanimod, which treats multiple sclerosis. Cramer sees enormous potential with this drug, which could even be worth billions.
Ozanimod is currently in Phase 3 trials as an oral treatment, and thus far, the data has indicated it is better than the competition oral treatment drug for MS.
Additionally, there are studies underway that have strong data indicating it could also treat ulcerative colitis and Crohn's disease, and in the long-term it could work for diseases like lupus or psoriasis, as well.
Could the healthy outlook translate into hefty investor profits? To find out, Cramer spoke with Receptos CEO Faheem Hasnain.
"Our efficacy data looks every bit as good, and, importantly, our safety profile seems to be a real improvement for patients with this disease," Hasnain said.
In the Lightning Round, Cramer gave his take on a few caller favorite stocks:
Restoration Hardware: "I think Restoration is a long-term play. We are not going to play this quarter to quarter because it's lumpy. You just want to own it, and stay with the guys, they know what they're doing. I might even buy it later tonight."